Primary testicular lymphoma
Authors:
Monika Motyčková; Vladimíra Vosáhlová; David Belada; Martin Šimkovič; Pavel Žák
Authors‘ workplace:
IV. interní hematologická klinika LF UK a FN Hradec Králové
Published in:
Vnitř Lék 2017; 63(6): 415-422
Category:
Reviews
Overview
Primary testicular lymphoma (PTL) is a rare form of extranodal lymphoma and accounts for approximately 1 to 2 % of all non-Hodgkin’s lymphoma and 5 % of testicular malignancies. PTL typically affects patients older than 60 years. The most common clinical symptom is painless scrotal swelling. The ultrasound of testicles followed by orchiectomy and histological and imunohistochemical examinations are the most important tools for diagnostic assessment. Diffuse large B cell lymphoma (DLBCL) is the most common histological type of PTL. Orchiectomy is an important part of the treatment, which includes the combination of systemic imunochemotherapy and prophylactic modalities such as radiotherapy of contralateral testis and central nervous system (CNS) prophylaxis. This combined treatment approach improved the outcome of patients with PTL, however, the high frequency of extranodal relapses including CNS involvement represents a significant problem. The prognosis of PTL still remains less favorable in comparison to the some subtypes of non-Hodgkin’s lymphomas.
Key words:
central nervous system lymphoma involvement prophylaxis – primary testicular lymphoma – prognosis – radiotherapy – relapse
Sources
1. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood 2014; 123(4): 486–493. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2013–10–530659>.
2. Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol 2008; 65(2): 183–189. Dostupné z DOI: <http://dx.doi.org/10.1016/j.critrevonc.2007.08.005>.
3. Horne MJ, Adeniran AJ. Primary Diffuse Large B-Cell Lymphoma of the Testis. Arch Pathol Lab Med 2011; 135(10): 1363–1367.Dostupné z DOI: <http://dx.doi.org/10.5858/arpa.2010–0158-RS>.
4. Kraan W, van Keimpema M, Horlings HM et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2014; 28(3): 719–720. Dostupné z DOI: <http://dx.doi.org/10.1038/leu.2013.348>.
5. Gundrum JD, Mathiason MA, Moore DB et al. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol 2009; 27(31): 5227–5232. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2009.22.5896>.
6. Fonseca R, Habermann TM, Colgan JP et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000; 88(1): 154–161. Dostupné z DOI: <http://dx.doi.org/10.1002/(SICI)1097–0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T>.
7. Deng L, Xu-Monette ZY, Loghavi S et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia 2016; 30(2): 361–372. Dostupné z DOI: <http://dx.doi.org/10.1038/leu.2015.237>.
8. Hasselblom S, Ridell B, Wedel H et al. Testicular lymphoma – a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol 2004; 43(8): 758–765. Dostupné z DOI: <http://dx.doi.org/10.1080/02841860410002851>.
9. Tondini C, Ferreri AJ, Siracusano L et al. Diffuse large-cell lymphoma of the testis. J Clin Oncol 1999; 17(9): 2854–2858. Dostupné z DOI: <http://dx.doi.org/ 10.1200/JCO.1999.17.9.2854>.
10. Vitolo U, Chiappella A, Ferreri AJ et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011; 29(20): 2766–2772. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.31.4187>.
11. Zouhair A, Herrmann E, Ugurluer G et al. Primary testicular lymphoma. Swiss Med Wkly 2010; 140: w13076. Dostupné z DOI: <http://dx.doi.org/10.4414/smw.2010.13076>.
12. Zucca E, Conconi A, Mughal T et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21(1): 20–27. Dostupné z DOI: <http://dx.doi.org/ 10.1200/JCO.2003.11.141>.
13. Belada D, Trněný M (eds) et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy III. 4th ed. HK Credit: Hradec Králové 2009. ISBN 978–80–86780–42–9.
14. Pectasides D, Economopoulos T, Kouvatseas G et al. Anthracycline-based chemotherapy of primary non-Hodgkin‘s lymphoma of the testis: the hellenic cooperative oncology group experience. Oncology 2000; 58(4): 286–292. Dostupné z DOI: <http://dx.doi.org/10.1159/000012114>.
15. Lagrange JL, Ramaioli A, Theodore CH et al. Non-Hodgkin‘s lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres. Ann Oncol 2001; 12(9): 1313–1319. Dostupné z DOI: <http://dx.doi.org/10.1023/A:1012224123385>.
16. Kridel R, Telio D, Villa D et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol 2016; 176(2): 210–221. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.14392>.
17. Booman M1, Szuhai K, Rosenwald A et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216(2): 209–217. Dostupné z DOI: <http://dx.doi.org/10.1002/path.2399>.
18. Hrudková M, Belada D, Smolej L et al. Primární lymfomy centrálního nervového systému. Vnitř Lék 2010; 56(8): 795–800.
19. Tilly H, Morschhauser F, Salles G et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013; 27(1): 252–255.Dostupné z DOI: <http://dx.doi.org/10.1038/leu.2012.172>.
20. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125(22): 3393–3400. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2015–02–567453>.
21. Lokesh KN, Sathyanarayanan V, Kuntegowdanahalli CL et al. Primary Diffuse large B-Cell lymphoma of testis: A single centre experience and review of literature. Urol Ann 2014; 6(3): 231–234. Dostupné z DOI: <http://dx.doi.org/10.4103/0974–7796.134277>.
22. Sýkorová A, Pytlík R, Móciková H et al. Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů – doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace). Klin Onkol 2016; 29(4): 295–302.
23. Abrahámová J. Testikulární zhoubné nádory – jsme snad u konce cesty? Vnitř Lék 2014; 60(Suppl 2): S8-S14.
24. Vural F, Cagirgan S, Saydam G et al. Primary testicular lymphoma. J Natl Med Assoc 2007; 99(11): 1277–1282.
25. Shipp MA. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 1994; 83(5): 1165–1173.
26. Mazloom A, Fowler N, Iyengar P et al. Primary Testicular Diffuse Large B-Cell Lymphoma, M.D. Anderson Cancer Center Experience. Blood 2009; 114: 2697 (abstract).
27. Mazloom A, Fowler N, Medeiros LJ et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma 2010; 51(7): 1217–1224. Dostupné z DOI: <http://dx.doi.org/10.3109/10428191003793358>.
28. Park BB, Kim JG, Sohn SK et al. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol 2007; 82(9): 840–845. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.20973>.
29. Seymour JF, Solomon B, Wolf MM et al. Primary large-cell non-Hodgkin‘s lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2(2):109–115.
30. Wang Y, Li ZM, Huang JJ et al. Three prognostic factors influence clinical outcomes of primary testicular lymphoma. Tumour Biol 2013; 34(1): 55–63. Dostupné z DOI: <http://dx.doi.org/10.1007/s13277–012–0510–4>.
31. Avilés A, Nambo MJ, Cleto S et al. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma 2009; 9(5): 386–389. Dostupné z DOI: <http://dx.doi.org/10.3816/CLM.2009.n.075>.
32. Avilés A, Neri N, Huerta-Guzmán J et al. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology 2004; 67(3–4): 211–214. Dostupné z DOI: <http://dx.doi.org/ 10.1159/000081319>.
33. Lantz AG, Power N, Hutton B et al. Malignant lymphoma of the testis: a study of 12 cases. Can Urol Assoc J 2009; 3(5): 393–398.
34. Kim J, Yoon DH, Park I et al. Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. Blood Res 2014; 49(3): 170–176. Dostupné z DOI: <http://dx.doi.org/10.5045/br.2014.49.3.170>.
35. Visco C, Medeiros LJ, Mesina OM et al. Non-Hodgkin‘s lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma 2001; 2(1): 40–46.
36. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379–791. Dostupné z DOI: http://dx.doi.org/10.1016/S1470–2045(06)70664–7>.
37. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19): 3121–3127. Dostupné z DOI: http://dx.doi.org/10.1200/JCO.2005.05.1003>.
38. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Engl J Med 2002; 346(4): 235–242. Dostupné z DOI: http://dx.doi.org/10.1056/NEJMoa011795>.
39. Telio D, Villa D, Shenkier T et al. Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. Blood 2011; 118(21): Abstrakt 780.
40. Zhang J, Chen B, Xu X Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 2014; 55(3): 509–514. Dostupné z DOI: <http://dx.doi.org/10.3109/10428194.2013.811239>.
41. Sarris AH, Vitolo U, Zucca E et al. Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG. Blood 2006; 108: Abstrakt 2454.
42. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011; 12(13): 1258–1266. Dostupné z DOI: <http://dx.doi.org/10.1016/S1470–2045(11)70140–1>,
43. Schmitz N, Zeynalova S, Nickelsen M et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol 2016; 34(26): 3150–3156. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2015.65.6520>.
44. Guirguis HR, Cheung MC, Mahrous M et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 2012; 159(1): 39–49. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2012.09247.x>.
45. Calimeri T, Cecchetti C, Vignat A et al. High-dose methotrexate (HD-MTX) as CNS prophylaxis significantly improves outcome in patients with high-risk diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2016; 27(6): 313–327. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdw375>.
46. Abramson JS, Hellmann M, Barnes JA et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010; 116(18): 4283–4290. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.25278>.
47. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin‘s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d‘Etudes des Lymphomes de l‘Adulte. Ann Oncol 2000; 11(6): 685–690.
48. Reinius M, Ahmad SS, Crawley C et al. High-Dose Methotrexate In The Treatment Of Primary Testicular Lymphoma. Blood 2013; 122(21): Abstrakt 5108.
49. Vitolo U, Chiappella A, Martelli M et al. Rituximab-CHOP plus intrathecal methotrexate and contralateral testis irradiation in untreated primary testicular diffuse large B-cell lymphoma: long term results of the IELSG-10 trial. Haematologica 2014; 156: Abstrakt 475.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 6
Most read in this issue
- Primary testicular lymphoma
- “Snags” connected with establishing the vitamin D
- Insulin pump in type 2 diabetes: B-cell focused treatment
- Two perspectives on venous thromboembolism in oncology